HylaPharm is a pioneering brand dedicated to developing innovative treatment options for both people and animals. With a focus on cancer therapies, HylaPharm aims to reverse tumor-induced immune suppression, transforming cold tumors into hot ones that can be effectively targeted by the immune system. This groundbreaking approach seeks to enhance the responsiveness to checkpoint inhibitors, which often fail in the majority of patients and can have severe side effects in those who do respond.

As a university spinout company, HylaPharm has achieved remarkable results in real cancers in pet dogs, demonstrating promising immune outcomes. Their team is based at the renowned BTBC incubator in Lawrence, Kansas, where they continue to push the boundaries of medical research and innovation. With numerous accomplishments to their name, including successful fundraising and garnering grants from esteemed organizations such as the National Cancer Institute, HylaPharm has proven their expertise in the field.

Their dedication to revolutionizing cancer treatment has the potential to change lives and improve healthcare outcomes for both humans and animals alike. Contact HylaPharm today to learn more about their cutting-edge advancements in cancer therapy